Direct medical cost analysis in the treatment of chronic kidney disease at Thong Nhat Dong Nai General Hospital in 2024
Các tác giả
DOI: https://doi.org/10.59294/HIUJS20250106Từ khóa:
direct medical cost, chronic kidney disease, factor associatedTóm tắt
Background: Chronic kidney disease (CKD) is rapidly becoming more prevalent among younger populations, posing significant impacts on health and socio-economic development. Therefore, analyzing direct medical costs (DMCs) in CKD treatment is essential. Objective: To analyze DMCs in the treatment of CKD at Thong Nhat Dong Nai General Hospital in 2024. Subjects and Methods: A cross-sectional descriptive study was conducted using retrospective electronic billing data of all CKD patients who met the sampling criteria at Thong Nhat Dong Nai General Hospital from January to December 2024. Results: The study analyzed data from 7,634 patients, with a mean age of 63.41 ± 13.76 years. Among them, 24.18% were diagnosed with stage 1 CKD. The average annual DMC per patient, per inpatient episode, and per outpatient visit was 14.02 million VND (95% CI: 13.28-14.77 million VND), 10.81 million VND (95% CI: 9.76-11.85 million VND), and 3.45 million VND (95% CI: 3.38-3.53 million VND), respectively. The majority of the costs were reimbursed by health insurance (ranging from 89.30% to 93.06%). Factors associated with DMCs included gender, CKD stage, insurance reimbursement rate, type of insurance coverage, and the presence of vascular comorbidities. Conclusion: The annual DMCs for CKD treatment were estimated to account for approximately 12.3% of the national GDP per capita in 2024, with inpatient DMCs representing around 9.48% and outpatient DMCs accounting for approximately 3.03%.
Abstract
Background: Chronic kidney disease (CKD) is rapidly becoming more prevalent among younger populations, posing significant impacts on health and socio-economic development. Therefore, analyzing direct medical costs (DMCs) in CKD treatment is essential. Objective: To analyze DMCs in the treatment of CKD at Thong Nhat Dong Nai General Hospital in 2024. Subjects and Methods: A cross-sectional descriptive study was conducted using retrospective electronic billing data of all CKD patients who met the sampling criteria at Thong Nhat Dong Nai General Hospital from January to December 2024. Results: The study analyzed data from 7,634 patients, with a mean age of 63.41 ± 13.76 years. Among them, 24.18% were diagnosed with stage 1 CKD. The average annual DMC per patient, per inpatient episode, and per outpatient visit was 14.02 million VND (95% CI: 13.28-14.77 million VND), 10.81 million VND (95% CI: 9.76-11.85 million VND), and 3.45 million VND (95% CI: 3.38-3.53 million VND), respectively. The majority of the costs were reimbursed by health insurance (ranging from 89.30% to 93.06%). Factors associated with DMCs included gender, CKD stage, insurance reimbursement rate, type of insurance coverage, and the presence of vascular comorbidities. Conclusion: The annual DMCs for CKD treatment were estimated to account for approximately 12.3% of the national GDP per capita in 2024, with inpatient DMCs representing around 9.48% and outpatient DMCs accounting for approximately 3.03%.
Tài liệu tham khảo
[1] Paul E. Stevens et al., "KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease," (in eng), Kidney Int, vol. 105, no. 4s, pp. S117-s314, Apr 2024.
[2] C. P. Kovesdy, "Epidemiology of chronic kidney disease: an update 2022," Kidney International Supplements, vol. 12, no. 1, pp. 7-11, 2022.
[3] T. Liyanage et al., "Prevalence of chronic kidney disease in Asia: a systematic review and analysis," BMJ Global Health, vol. 7, no. 1, p. e007525, 2022.
[4] S. Randall et al., "Estimating the cost of chronic kidney disease in Australia," BMC Health Services Research, vol. 24, no. 1, p. 1468, 2024/11/26 2024.
[5] M. Nisar et al., "The direct cost of chronic kidney disease (CKD) reported in Asian countries; a systematic literature review," Cost Effectiveness and Resource Allocation, vol. 22, no. 1, p. 65, 2024/09/05 2024.
[6] N. V. Đại, T. H. Khải, V. Q. L. Duyên, và N. P. Hưng, "Nghiên cứu chi phí trực tiếp y tế và các yếu tố liên quan của bệnh nhân suy thận mạn giai đoạn cuối điều trị ngoại trú tại Bệnh viện đa khoa tỉnh Kiên Giang năm 2022-2023," Tạp chí Y học Việt Nam, tập. 530, số. 1B, tr. 135-139, 2023.
[7] H. Y. Nguyen-Thi et al., "The Economic Burden of Chronic Kidney Disease in Vietnam," (in eng), Health Serv Insights, vol. 14, p. 11786329211036011, 2021.
[8] S. H. Suh and S. W. Kim, "Dyslipidemia in patients with chronic kidney disease: an updated overview," Diabetes metabolism journal, vol. 47, no. 5, pp. 612-629, 2023.
[9] A. Francis et al., "Chronic kidney disease and the global public health agenda: an international consensus," Nature Reviews Nephrology, vol. 20, no. 7, pp. 473-485, 2024.
[10] S. H. Kim, M. W. Jo, D. S. Go, D. R. Ryu, and J. Park, "Economic burden of chronic kidney disease in Korea using national sample cohort," Journal of nephrology, vol. 30, no. 6, pp. 787-793, 2017.
[11] N. H. N. Lan và P. V. Hưng, "Chi phí điều trị bệnh suy thận mạn giai đoạn cuối lọc máu chu kỳ tại Bệnh viện Quận Thủ Đức," Tạp chí Y Dược học, tập. 6, số. 4, tr. 34-40, 2016.
[12] Bộ Y Tế. (2025). Bệnh suy thận ngày càng gia tăng và trẻ hóa. Hà Nội.
[13] I. A. Bradacs et al., "Epidemiology and hospitalization costs of chronic kidney disease in Romania," Health Economics Review, vol. 15, no. 1, p. 38, 2025/04/25 2025.
Tải xuống
Tải xuống: 0




